Prescription patterns for diabetes mellitus and therapeutic implications: A population-based analysis;Padrões de prescrição e implicações terapêuticas para o diabetes melito: Análise de base populacional

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 56, Issue 2, 2012, Pages 120-127

  Guidoni, Camilo Molino ^a   de Sá Borges, Anna Paula ^a   de Freitas, Osvaldo ^a   Pereira, Leonardo Régis Leira ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Database; Diabetes mellitus; Drug prescriptions; Drug use; Pharmacoepidemiology; Unified health system

Indexed keywords

EID: 84861305999     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302012000200005     Document Type: Article

References (34)

1. International Diabetes Federation. Diabetes atlas [Internet]. 4th ed. Brussels: International Diabetes Federation; 2009. Available from: http://www.diabetesatlas.org/content/diabetes. Accessed on: Sept 7, 2011.
2. Brazilian Health Ministry. National relation of essential medicines. 7th ed. Brasília, DF: Brazilian Health Ministry; 2010.
3. Bahia LR, Araujo DV, Schaan BD, Dib SA, Negrato CA, Leão MP, et al. The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system. Value Health. 2011;14(1):S137-40.
4. WHO International Working Group for Drug Statistics Methodology; WHO Collaborating Centre for Drug Statistics Methodology; WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. Introduction to drug utilization research. Geneva; 2003.
5. Strom BL. What is pharmacoepidemiology? In: Strom BL, editor. Pharmacoepidemiology. 4th ed. Chichester: John Wiley & Sons; 2000. p. 3-15.
6. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2007;16(4):393-401.
7. Roten I, Marty S, Beney J. Electronic screening of medical records to detect inpatients at risk of drug-related problems. Pharm World Sci. 2010;32(1):103-07.
8. Brazilian Health Ministry. SUS Full 20 years with new challenges: interview of the Minister of Health Jose Gomes Health Agency. Rev Inst Santa Cat. 2008;1(1):7-9.
9. World Health Organization Collaborating Centre for Drug Statistics Methodology [Internet]. Available from: http://www.whocc.no/atc_ddd_index/. Accessed on: Sept 7, 2011.
10. Dipiro J, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York: Editora McGraw-Hill; 2009. p. 2581.
11. Glucophage® (metformin hydrochloride) tablets. Glucophage®XR (metformin hydrocloride) extended-release tablets. Princeton: Bristol-Myers Squibb; 2009. (Bula de remédio)
12. Micronase®: glyburide tablets, USP: for oral use. New York: Pfizer, 2010. (Bula de remédio)
13. Sociedade Brasileira de Diabetes. Tratamento e acompanhamento do diabetes mellitus. Diretrizes da Sociedade Brasileira de Diabetes. Rio de Janeiro; 2007.
14. Pagkalos EM. Combinations of insulin and oral hypoglycemic agents in diabetes mellitus type 2. Diabetes Res Clin Pract. 2011;93:S100-1.
15. Vauzelle-Kervroëdan F, Javoy F, Forhan A, Fender P, Eschwège E. Pharmacoepidemiology of diabetes: assessment of good use of oral antidiabetic drugs. Diabetes Metab. 2000;26(6):63-8.
16. Bosi PL, Carvalho AM, Contrera D, Casale G, Pereira MA, Gronner MF, et al. Prevalence of diabetes and impaired glucose tolerance in the urban population of 30 to 79 years of the city of São Carlos, São Paulo. Arq Bras Endocrinol Metabol. 2009;53(6):726-32.
17. Baviera M, Monesi L, Marzona I, Avanzini F, Monesi G, Nobili A, et al. Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy's Lombardy Region: a large population-based study. Diabetes Res Clin Pract. 2011;93:I23-30.
18. Alba JEM, Escobar JCM, Escobar GM. Patrones de prescripción de antidiabéticos em um grupo de pacientes colombianos. Rev Panam Salud Publica. 2007;22:124-31.
19. Yurgin N, Secnik K, Lage MJ. Antidiabetic prescriptions and glycemic control in german patients with type 2 diabetes mellitus: a retrospective database study. Clin Ther. 2007;29(2):316-25.
20. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2011;34(1):S11-S61.
21. Burgers JS, Bailey JV, Klazinga NS, Van Der Bij AK, Grol R, Feder G. Inside guidelines: comparative analysis of recommendations and evidence in diabetes guidelines from 13 countries. Diabetes Care. 2002;25(11):1933-9.
22. Sociedade Brasileira de Diabetes. Consenso Brasileiro sobre Diabetes 2002: diagnóstico e classificação do diabetes melito e tratamento do diabetes melito do tipo 2. Rio de Janeiro: Diagraphic; 2003.
23. United Kingdom Prospective Diabetes Study Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group. Diabetes Care. 1998;21(1):87-92.
24. Mu PW, Chen YM, Lu HY, Wen XQ, Zhang YH, Xie RY, et al. Effects of a combination of oral antidiabetes drugs with basal insulin therapy on b-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes. Diabetes Metab Res Rev. 2011;28:236-40.
25. Doucet J. Use of antidiabetic drugs in elderly patients. Diabetes Metab. 2005; 31:5 S98-104.
26. Tosi F, Muggeo M, Brun E, Spiazzi G, Perobelli L, Zanolin E, et al. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. Metabolism. 2003;52(7):862-7.
27. Rochester CD, Leon N, Dombrowski R, Haines ST. Collaborative drug therapy management for initiating and adjusting insulin therapy in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2010;67(1):42-8.
28. Pogach LM. Pharmacoepidemiology of insulin initiation in diabetes care. CMAJ. 2009;180(13):1287-8.
29. Hahr AJ, Molitch ME. Optimizing insulin therapy in patients with type 1 and type 2 diabetes mellitus: optimal dosing and timing in the outpatient setting. Dis Mon. 2008;15(6):543-50.
30. Ryan GJ. Overcoming insulin "resistance": assisting patients in transitioning to insulin therapy. Am J Health Syst Pharm. 2010;67(6):441-4.
31. Gerich JE. Oral hypoglycemic agents. N Engl J Med. 1989;321(18): 1231-45.
32. Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, De Rosa N, et al. Metformin for obese insulin-treated diabetic patients: improvement in glycemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol. 1993;44(2):107-12.
33. Melander A, Folino-gallo P, Walley T, Schwabe U, Groop PH, Klaukka T, et al. Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels. Diabetologia. 2006;49(9):2024-9.
34. Boccuzzi SJ, Wogen J, Fox J, Sung JCY, Shah AB, Kim J. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care. 2001;24(8):1411-5.